Time to reperfusion: The critical modulator in thrombolysis and primary angioplasty

Journal of Thrombosis and Thrombolysis

Volumn 3, Issue 2, 1996, Pages 117-125

  Cannon, Christopher P ^a   Braunwald, Eugene ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Primary angioplasty; Thrombolysis; Time to treatment

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT; HEPARIN; STREPTOKINASE; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANGIOPLASTY; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONFERENCE PAPER; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; PRIORITY JOURNAL; SURVIVAL; TIME; TREATMENT OUTCOME;

EID: 0029889896     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00132404     Document Type: Conference Paper

References (69)

1. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2:349-360.
3. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673-682.
4. Braunwald E. Myocardial reperfusion, limitation of infarct size, reduction of left ventricular dysfunction, and improved survival: Should the paradigm be expanded? Circulation 1989;79:441-444.
5. Braunwald E. The open-artery theory is alive and well - again. N Engl J Med 1993;329:1650-1652.
6. Reimer KA, Lowe JE, Rasmussen NM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs. duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
7. Rentrop KP, Blanke H, Karsch KR, Kreuzer H. Initial experience with transluminal recanalization of the recently occluded infarct-related coronary artery in acute myocardial infarction. Comparison with conventionally treated patients. Clin Cardiol 1979;2:92-105.
8. Ganz W, Buchbinder. N, Marcus H, et al. Intracoronary thrombolysis in evolving myocardial infarction. Am Heart J 1981;101:4-13.
9. Stadius ML, Davis K, Maynard C, Ritchie JL, Kennedy JW. Risk stratification for 1 year survival based on characteristics identified in the early hours of acute myocardial infarction. Circulation 1986;74:701-711.
10. Dalen JE, Gore JM, Braunwald E, et al. Six and twelve-month follow-up of the Phase I Thrombolysis in Myocardial Infarction (TIMI) Trial. Am J Cardiol 1988;62:179-185.
11. Belenkie I, Thompson CR, Manyari DE, et al. Importance of effective, early and sustained reperfusion during acute myocardial infarction. Am J Cardiol 1989;63:912-916.
12. Flygenring BP, Sheehan FH, Kennedy JW, Dodge HT, Braunwald E, for the TIMI Investigators. Does arterial patency 90 minutes following thrombolytic therapy predict 42 day survival? (abstract) J Am Coll Cardiol 1991;17(Suppl A):275A.
13. Karagounis L, Sorensen SG, Menlove RL, Moreno F, Anderson JL, for the TEAM-2 Investigators. Does Thrombolysis in Myocardial Infarction (TIMI) perfusion grade 2 represent a mostly patent artery or a mostly occluded artery? Enzymatic and electrocardiographic evidence from the TEAM-2 Study. J Am Coll Cardiol 1992;19:1-10.
14. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL, for the TEAM-3 Investigators. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: Ventriculographic, enzymatic and electrocardiographic evidence from the TEAM-3 Study. Circulation 1993;87:1829-1839.
15. Cannon CP, McCabe CH, Diver DJ, et al. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J Am Coll Cardiol 1994;24:1602-1610.
16. Cannon CP, McCabe CH, Henry TD, et al. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial. J Am Coll Cardiol 1994;23:993-1003.
17. Lincoff AM, Topol EJ, Califf RM, et al. Significance of a coronary artery with Thrombolysis in Myocardial Infarction grade 2 flow "patency" (outcome in the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) trials). Am J Cardiol 1995;75:871-876.
18. The GUSTO Angiographie Investigators. The comparative effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615-1622.
19. Simes RJ, Topol EJ, Holmes DR, et al. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation 1995;91:1923-1928.
20. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) Trial; Phase I findings. N Engl J Med 1985; 312:932-936.
21. Cannon CP, Braunwald E. GUSTO, TIMI and the case for rapid reperfusion. Acta Cardiol 1994;49:1-8.
22. Gruppo Italiano per Io Studio della Sopravvivenza nell'Infarto Miocardico: GISSI-2. A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71.
23. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet 1990;336:71-75.
24. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-770.
25. Cannon CP, Love TW, McCabe CH, et al. TNK-tissue plasminogen activator in myocardial infarction (TIMI) 10: Results of the initial patients in the TIMI 10 Pilot - a Phase 1, pharmacokinetics trial (abstract). Circulation 1995; 92(Suppl I):I-415.
26. Weaver WD, Bode C, Burnett C, et al. Reteplase vs. Alteplase Patency Investigation During myocardial infarction trial (RAPID 2) (abstract). J Am Coll Cardiol 1995;Special Issue:87A.
27. Ohman EM, Kleiman NS, Talley JD, et al. Simultaneous platelet glycoprotein IIb/IIIa integrin blockade with accelerated tissue plasminogen activator in acute myocardial infarction (abstract). Circulation 1994;90:I-564.
28. Cannon CP, Antman EM, Walls R, Braunwald E. Time as an adjunctive agent to thrombolytic therapy. J Thromb Thrombolysis 1994;1:27-34.
29. Timm TC, Ross R, McKendall GR, Braunwald E, Williams DO, and the TIMI Investigators. Left ventricular function and early cardiac events as a function of time to treatment with t-PA: A report from TIMI II (abstract). Circulation 1991;84:II-230.
30. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. Circulation 1995;91:1659-1668.
31. Topol EJ, Califf RM, Lee KL, on behalf of the GUSTO Investigators. More on the GUSTO trial (letter). N Engl J Med 1994;331:277-278. Published errata appear in N Engl J Med 1994;331:687, 1323.
32. O'Keefe JH, Rutherford BD, McConahay DR, et al. Early and late results of coronary angioplasty without antecedent thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1989;64:1221-1230.
33. Cannon CP. Time to treatment: A crucial factor in thrombolysis and primary angioplasty. J Thromb Thrombolysis, in press.
34. Braunwald E. Optimizing thrombolytic therapy of acute myocardial infarction. Circulation 1990;82:1510-1513.
35. Gersh BJ, Anderson JL. Thrombolysis and myocardial salvage. Results of clinical trials and the animal paradigm - paradoxic or predictable? Circulation 1993;88:296-306.
36. National Heart Attack Alert Program Coordinating Committee-60 Minutes to Treatment Working Group. Emergency department: Rapid identification and treatment of patients with acute myocardial infarction. Ann Emerg Med 1994;23:311-329.
37. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Patient/bystander recognition and action: Rapid identification and treatment of acute myocardial infarction. National Institute of Health; 1993: NIH Publication No. 93-3303.
38. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Staffing and equipping emergency medical services systems: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:58-65.
39. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. Emergency medical dispatching: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:67-73.
40. National Heart Attack Alert Program Coordinating Committee Access to Care Subcommittee. 9-1-1: Rapid identification and treatment of acute myocardial infarction. Am J Emerg Med 1995;13:188-195.
41. Lambrew CT. The National Heart Attack Alert Program: A review. J Thromb Thrombolysis 1994;1:153-156.
42. Gaspoz J-M, Unger P-F, Urban P, et al. Impact of a public campaign on pre-hospital time delays in suspected acute myocardial infarction (abstract). Circulation 1993;88:I-13.
43. Blohm M, Herlitz J, Hartford M, et al. Consequences of a media campaign focusing on delay in acute myocardial infarction. Am J Cardiol 1992;69:411-413.
44. Weaver WD, Eisenberg MC, Martin JS, et al. Myocardial Infarction Triage and Intervention Project - Phase I: Patient characteristics and feasibility of prehospital initiation of thrombolytic therapy. J Am Coll Cardiol 1990;15: 925-931.
45. Karagounis L, Ipsen SK, Jessop MR, et al. Impact of field-transmitted electrocardiography on time to in-hospital thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1990;66:786-791.
46. Lambrew CT, Weaver WD, French WJ, Bowlby L, Rubison M, for the National Registry of Myocardial Infarction (NRMI). Impact of hospital protocols on time to treatment with thrombolytic therapy (door to drug time) (abstract). J Am Coll Cardiol 1994;Special Issue:14A.
47. Rawles J, on behalf of the GREAT Group. Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT). J Am Coll Cardiol 1994;23:1-5.
48. The European Myocardial Infarction Project Group. Pre-hospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Eng J Med 1993;329: 383-389.
49. Sharkey SW, Brunette DD, Ruiz E, et al. An analysis of time delays preceding thrombolysis for acute myocardial infarction. JAMA 1989;262:3171-3174.
50. Kline EM, Smith DD, Martin JS, for the GUSTO Time to Treatment Study Group. GUSTO Time to Treatment Substudy: Results of the phase II randomized trial (abstract). Circulation 1993;88:I-337.
51. Cannon CP, Henry TD, Schweiger MJ, et al. Current management of ST elevation myocardial infarction and outcome of thrombolytic ineligible patients: Results of the multicenter TIMI 9 Registry (abstract). J Am Coll Cardiol 1995; Special Issue:231A.
52. Ellerbeck EF, Jencks SF, Radford MJ, et al. Quality of care for medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. JAMA 1995;273:1509-1514.
53. Pell ACH, Miller HC, Robertson CE, Fox KAA. Effect of "fast track" admission for acute myocardial infarction on delay to trombolysis. Br Med J 1992;304:83-87.
54. Lambrew CT. Emergency department triage of patients with nontraumatic chest pain. ACC Curr J Rev 1995;4: 61-62.
55. Krall SP, Reese CL, Donahue L. Effect of continuous quality improvement methods on reducing triage time to thrombolytic interval for acute myocardial infarction. Acad Emerg Med 1995;2:603-609.
56. Kopecky SL, Siska MJ, Jurek JA, et al. Method of reducing emergency room time to treatment of acute myocardial infarction (abstract). J Am Coll Cardiol 1995;Special Issue: 206.
57. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328:673-679.
58. Zijlstra F, de Boer MJ, Hoorntje JCA, Reiffers S, Reiber JHC, Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med 1993;328:680-684.
59. Rogers WJ, Dean LS, Moore PB, et al. Comparison of pri-mary angiopiasty versus thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1994;74:111-118.
60. Tiefenbrunn AJ, Chandra NC, French WJ, Rogers WJ. Ex-perience with primary PTCA compared to alteplase in pa-tients with acute myocardial infarction (abstract). Circulation 1995;92(Suppl I):I-138.
61. Every N, Weaver WD, Parsons L, Martin JS, for the MITI Project Investigators. Direct PTCA vs. thrombolysis: Im-mediate and one year outcome and procedure utilization for the two treatment strategies (abstract). Circulation 1995; 92(Suppl I):I-138.
62. Neuhaus K-L, Vogt A, Harmjanz, D, v. Leitner E, Wirtz-feld A, Neiderer W, Merx W, for the ALKK-study group: Primary angioplasty for acute myocardial infarction: results from a German multicenter registry, (abstract) J Am Coll Cardiol 1996;27:62A.
63. de Boer MJ, Suryapranata H, Hoorntje JCA, et al. Limitation of infarct size and preservation of left ventricular function after primary coronary angioplasty compared with intravenous streptokinase in acute myocardial infarction. Circulation 1994;90:753-761.
64. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993;328:685-691.
65. O'Neill WW, Brodie BR, Ivanhoe R, et al. Primary coronary angioplasty for acute myocardial infarction (the Primary Angioplasty Registry). Am J Cardiol 1994;73: 627-634.
66. Grines C, Marsalese D, Brodie B, et al. Acute cath provides the best method of risk stratifying MI patients (abstract). Circulation 1995;92(Suppl I):I-531.
67. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. Drugs 1992;44:293-325.
68. Neuhaus K-L, Von Essen R, Tebbe U, et al. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC Patency Study (TAPS). J Am Coll Cardiol 1992; 19:885-891.
69. Cannon CP, Lambrew CT, Tiefenbrunn AJ, et al. Influence of door-to-balloon time on mortality in primary angioplasty Results in 3,648 patients in the Second National Registry of Myocardial Infarction (NRMI-2) (abstract). J Am Coll Cardiol 1996;27:61a-62a.